Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-drug conjugates - ImmunoGen

Next Previous
Drug Profile

Research programme: antibody-drug conjugates - ImmunoGen

Alternative Names: Anti-c-Met-DGN 549; Anti-c-Met-DM4; anti-CD123 ADC - Immunogen; Anti-CD33-3m; Anti-CD56-3m; Anti-cMet antibody-drug conjugate; Anti-EGFR-3m; Anti-FRα-3m; CD19-targeting antibody-drug conjugate; huB4-DGN462; hucMet-DM4; hucMet27-DGN 549; IGN P1; IGNs-ADCs; M-DGN549; M9346A NL DM

Latest Information Update: 17 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; DNA cross linking agents; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 17 Oct 2025 Research programme: antibody-drug conjugates is still in preclinical development for Solid tumours in USA (Parenteral)
  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 28 Dec 2022 Preclinical development is ongoing USA (Immunogen pipeline, December 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top